Tracking COVID-19 Variants and Disease Presentation Over the Pandemic Course

February 15, 2024

Featured image for “Tracking COVID-19 Variants and Disease Presentation Over the Pandemic Course”

Since emerging in late 2019, the novel SARS-CoV-2 virus behind the COVID-19 pandemic has continued evolving through various new “variants”. These versions differ genetically due to mutations accumulating in the pathogen’s RNA over transmission cycles. Understanding COVID-19 variant traits – especially regarding contagiousness, disease severity, and immunity evasion – remains essential for informing ongoing public health measures globally. This article reviews the notable SARS-CoV-2 variants detected to date along with what’s known about their key characteristics. We also examine how COVID-19 symptoms and presentation have shifted from initial observations as new variants rose to prominence across different waves.

Brief Primer on Viral Variant Terminology

In virology, a “strain” references a viral subtype with minor genetic differences not expected to change core traits of transmission or virulence. “Variants”, however, exhibit key mutations in crucial spots like the spike protein influencing infection dynamics and illness patterns. Those variants garnering urgent attention from health authorities are dubbed “Variants of Concern” (VOCs) given indications of:

  • Increased infectiousness – Meaning more efficient human-to-human spread.
  • Enhanced disease severity – Causing comparatively worse outcomes.
  • Immune escape – More capable of overcoming existing vaccine/natural immunity.

So variant monitoring seeks to rapidly identify and characterize new viral offspring that could require tweaks to diagnostic testing, treatments, vaccines, or mitigation policies as the pandemic progresses.

Original Virus and Alpha: Initial Phase of Pandemic

The COVID-19 outbreak traced back to Wuhan, China kicked off from infection with the “original” or “ancestral” viral strain. This wildtype version initiated global spread in early 2020 before being displaced by newer variants.

After emerging strains like Epsilon and Zeta briefly circulated in specific regions, the first VOC dubbed “Alpha” (B.1.1.7) arose in the UK by late 2020. Alpha ignited case spikes given a suite of mutations enabling around 50% higher transmission efficiency. It also caused more severe disease on average compared to the original virus.

During this initial pandemic phase up to early 2021, the core constellation of COVID-19 symptoms centered around:

  • Fever
  • Cough
  • Fatigue
  • Anosmia (loss of smell) – A hallmark early sign

Milder symptoms like sore throat, headaches, muscle pain, vomiting, and diarrhea occurred commonly too. Hospital data revealed those over age 60 at highest risk for critical illness, though younger unvaccinated people increasingly required intensive care once variants accelerated community attack rates.

Delta’s Arrival

Through latter 2021, the “Delta” (B.1.617.2) variant surged out of India to become the globally dominant strain based on supercharged infectiousness augmenting its transmission perhaps twofold beyond Alpha. Delta also demonstrated more frequent breakthrough infections in fully vaccinated individuals versus prior variants – though remaining less likely to cause severe disease among the vaccinated.

Beyond Delta further increasing hospitalizations among younger groups again, this variant may have also shifted COVID-19’s primary symptoms to some degree:

  • Cough and sore throat potentially grew more prominent
  • Loss of smell declined in prominence

Though fatigue, fever, and headaches maintained prevalence. Long COVID risks also seemingly increased compared to ancestral virus infections. Delta essentially delivered a “double whammy” of rising magnitude of community outbreaks and nastier cases among the unvaccinated.

Omicron Family: Immune Evasion and Sublineages

In late 2021, the furiously-spreading “Omicron” (B.1.1.529) variant emerged in South Africa to replace Delta as the global driver of SARS-CoV-2 transmission based on its extreme infectiousness, estimated at more than threefold higher than the formerly dominant Delta.

While Omicron infection generally causes less severe disease relative to prior variants, its unprecedented penetration into populations resulted in record hospitalizations at times.

Omicron also exhibits much greater “immune escape” attuned to overcoming existing vaccine and natural infection antibody defenses. This propels reinfection risks relative to earlier variants. Yet vaccine boosters provide restored protection by enhancing B and T cell immunity against severe outcomes.

Over 2022-2023, Omicron further evolved into various “sublineages”(offshoots) like BA.5 demonstrating even higher intrinsic contagiousness and relative reinfection capacity while remaining somewhat less virulent.

In terms of common symptoms, core Omicron presentations seem closely in line with prior variants. However, disease duration may skew shorter compared to Delta. Loss of taste or smell also appears less pronounced in Omicron cases, while nausea and vomiting crop up more frequently.

Most recently, BQ.1 and XBB sublineages have raised international concern given rapid spread driven by immunological evasion. Thus the virus persists in its unnerving shape-shifting nature.

Examining Key Unknowns Around Emerging SARS-CoV-2 Variants

Are we likely to see a “yearly COVID season” going forward similar to influenza?

If SARS-CoV-2 continues mutating significantly year-to-year like the flu, then updated vaccines targeting dominant circulating variants may be needed regularly to prevent seasonal case spikes – especially protecting vulnerable groups.

At what point would a variant’s traits require developing altogether new vaccines?

If future variants emerge with mutations enabling escape from both infection-conferred and current vaccine-derived immunity, that could necessitate retooled vaccines activating different immune defenses against those dramatically distinct strains.

Can variant vaccines be developed quickly enough to get ahead of community spread?

An optimized vaccine development pipeline can potentially yield updated shots in around 100 days. But distributing and administering new vaccines globally before variants grow to represent over 25% of cases poses extreme logistical challenges.

Are diagnostic tests able to reliably detect every circulating variant?

While core PCR diagnostics detect predominant variants, the diversity of new sublineages raises concerns on missed cases. Thus surveillance monitoring must rapidly confirm tests’ sensitivity to emerging derivatives.

At this stage over three years into the pandemic, SARS-CoV-2 continues revealing its evolutionary dexterity – leaving long term projections on transmission patterns and disease risk uncertain pending variant trajectories.

Key Takeaways

  • SARS-CoV-2 variants like Omicron exhibit key mutations influencing infectiousness, disease severity, and immunity evasion.
  • Early COVID-19 hallmarks centered around fever, cough, fatigue, and anosmia, though later surges spotlighted more variable presentation.
  • The astoundingly contagious Omicron variant and sublineages still cause less proportionate severe disease relative to prior strains.
  • Questions around vaccines targeting variants, speed of variant spread, test efficacy, and future endemicity remain outstanding.
  • With COVID-19 dynamics shaped fundamentally by ever-changing variants, continued vigilance and adaptation is mandatory moving forward.

Monitoring for novel viral variants and tracking associated symptom patterns remains vital for understanding the pandemic phase the globe has entered and responding accordingly. Until transmission drops definitively worldwide offering less replication opportunities for SARS-CoV-2, minding the virus’ inevitable evolution through its error-prone copying machinery represents rule number one for decision makers working to finally gain the upper hand against this perpetual microbial foe.

Rate this post

Related articles


Cold Plasma System

The world's first handheld cold plasma device

Learn More

Made in USA